Y's Therapeutics, Inc. Initiates Phase II Trial With YSPSL in Liver Transplant Patients for Prevention of Ischemic Reperfusion (I/R) Injury
5/2/2007 10:38:01 AM
TOKYO and BURLINGAME, CA -- (MARKET WIRE) -- May 02, 2007 -- Y's Therapeutics, a privately held biopharmaceutical company, announced the initiation of a Phase II clinical trial of its lead compound, YSPSL, for prevention of ischemic reperfusion injury (I/R) in liver transplant patients. The clinical trial is a randomized, double-blind, placebo-controlled study designed to enroll 12 patients undergoing cadaveric orthotopic liver transplantation at Dumont UCLA Transplant Center, a leading US liver transplant center.
comments powered by